These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10528981)

  • 1. The maximum pharmacodynamic effect as a response parameter: pharmacokinetic considerations.
    Leopold CS
    J Pharm Pharmacol; 1999 Sep; 51(9):999-1008. PubMed ID: 10528981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cream and ointment bases on the steady state penetration of permeants through intact skin: the reciprocal of the onset time of a pharmacodynamic effect as parameter of response.
    Leopold CS
    Int J Cosmet Sci; 2000 Apr; 22(2):133-45. PubMed ID: 18503468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data?
    Leopold CS
    Pharm Acta Helv; 1998 Jun; 73(1):63-7. PubMed ID: 9708038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of drug action in disease states. XXI. Relationship between drug infusion rate and dose required to produce a pharmacologic effect.
    Klockowski PM; Levy G
    J Pharm Sci; 1987 Jul; 76(7):516-20. PubMed ID: 3668811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of erythema onset after application of methyl nicotinate ointments as response parameter: influence of penetration kinetics and enhancing agents.
    Remane Y; Leopold CS
    Skin Pharmacol Physiol; 2006; 19(6):303-10. PubMed ID: 16931897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous penetration enhancement and its quantification.
    Bach M; Lippold BC
    Eur J Pharm Biopharm; 1998 Jul; 46(1):1-13. PubMed ID: 9700018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
    Tuk B; Danhof M; Mandema JW
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of the FDA guidance for industry--'Topical dermatologic corticosteroids: in vivo bioequivalence'.
    Leopold CS
    Eur J Pharm Biopharm; 2003 Jul; 56(1):53-8. PubMed ID: 12837481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.
    Trocóniz IF; Armenteros S; Planelles MV; Benítez J; Calvo R; Domínguez R
    Clin Pharmacokinet; 2000 Jun; 38(6):505-18. PubMed ID: 10885587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic relationship.
    Baggot JD
    Ann Rech Vet; 1990; 21 Suppl 1():29S-40S. PubMed ID: 2080844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gestagens: some problems.
    Fotherby K
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):323-8. PubMed ID: 2115297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
    Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.
    Gabrielsson J; Jusko WJ; Alari L
    Biopharm Drug Dispos; 2000 Mar; 21(2):41-52. PubMed ID: 11100906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
    Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
    Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.